Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Perugia – page 6

283 clinical trials in Perugia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Perugia at a glance
283
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

283 trials in Perugia

Open in trial search

Acute myeloid leukaemia

Recruiting

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Small cell lung cancer extensive stage

Recruiting

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Metastatic renal cell carcinoma

Recruiting

Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcarnitine hydrochloride
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Acute myeloid leukaemia refractory+1

Recruiting

Study on the Safety and Effectiveness of Eltanexor for Patients with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Eltanexor
  • Sponsor:Azienda Ospedaliero Universitaria Delle Marche

Non-small cell lung cancer

Recruiting

Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Fondazione Ricerca Traslazionale

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Ovarian cancer

Recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Squamous cell carcinoma of skin

Recruiting

Study on Cemiplimab for Patients with High-Risk Stage III/IV Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione Melanoma Onlus

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib for Adults with Chronic Lymphocytic Leukemia and Heart Issues

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia

Recruiting

Study of Ibrutinib for Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia or Similar Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Perugia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer, leukemia, and breast cancer treatments. Studies include evaluating new combination therapies and targeted treatments for various cancer types.

  • Advanced NSCLC treatments with immunotherapy combinations
  • Novel approaches for acute myeloid leukemia
  • Breast cancer endocrine therapy optimization

Multiple trials are investigating breakthrough treatments for both early-stage and metastatic cancers.

02 Dermatology Studies

Research focusing on chronic skin conditions, including allergic contact dermatitis, hidradenitis suppurativa, and prurigo nodularis.

  • Metal allergen patch testing protocols
  • Innovative treatments for inflammatory skin disorders
  • Novel therapeutic approaches for chronic skin conditions

Trials aim to improve diagnostic methods and develop targeted therapies for persistent skin conditions.

03 Autoimmune Disorders

Studies examining treatments for various autoimmune conditions, including psoriatic arthritis and non-infectious uveitis.

  • Evaluation of biological therapies
  • Novel treatment combinations
  • Disease progression monitoring

Research focuses on developing more effective treatments with fewer side effects for chronic autoimmune conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.